SK-N-BE(2)-M17 is a twice-sub-cloned cell line derived from the SK-N-BE(2) neuroblastoma cell line. Like the parental cell line, these cells display MYCN amplification. Treatment with trans-retinoic acid differentiates these cells into a distinct neuronal phenotype. These cells display high levels of tyrosine hydroxylase activity and moderate dopamine-b-hydroxylase activity.
This cell line is a subclone of the SK-N-BE(2) neuroblastoma cell line. The parental cell line was established in 1972 from a metastatic site (bone marrow) in a two-year-old Caucasian male with malignant neuroblastoma.
- June L. Biedler, PhD, former Chairman, Cell Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Barbara A. Spengler, formerly at Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Ciccarone V et al. (1989) Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Research 49: 219-225 (PubMed ID: 2535691)
- Andres D et al. (2013) Morphological and functional differentiation in BE(2)-M17 human neuroblastoma cells by treatment with trans-retinoic acid. BMC Neuroscience 14: 49 (PubMed ID: 23597229)
This cell line may be licensed nonexclusively for research or commercial purposes.
Tingting Zhang-Kharas, PhD